Skip to main navigation Skip to search Skip to main content

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis

  • Daniel J. Deangelo
  • , Ruben A. Mesa
  • , Warren Fiskus
  • , Ayalew Tefferi
  • , Carole Paley
  • , Martha Wadleigh
  • , Ellen K. Ritchie
  • , David S. Snyder
  • , Kebede Begna
  • , Siddhartha Ganguly
  • , Michael S. Ondovik
  • , Jessica Rine
  • , Kapil N. Bhalla

Research output: Contribution to journal › Article › peer-review

Abstract

Myelofibrosis (MF) is a Philadelphia chromosome-negative stem cell myeloproliferative neoplasm (MPN) associated with cytopenias, splenomegaly, constitutional symptoms, and poor prognosis. MF patients commonly express JAK2 V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF. This study evaluated panobinostat, a pan-deacetylase inhibitor that depletes JAK2 V617F levels and JAK/STAT signalling in MPN cells, in patients with primary MF, post-essential thrombocythaemia MF, and post-polycythaemia vera MF. Patients received panobinostat 40 mg administered three times per week. Dose reductions were permitted for toxicities. The primary endpoint was response rate at 6 months using International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria. Analyses of peripheral blood cells from treated patients revealed that panobinostat inhibited JAK/STAT signalling, decreased inflammatory cytokine levels, and decreased JAK2 V617F allelic burden. However, panobinostat was poorly tolerated at the dose and schedule evaluated, and only 16 of 35 patients completed ≥2 cycles of treatment. One patient (3%) achieved an IWG-MRT response. Common adverse events were thrombocytopenia (71·4%) and diarrhoea (80·0%). Although molecular correlative analyses suggested that panobinostat inhibits key intracellular targets, limited clinical activity was observed because of poor tolerance.

Original languageEnglish (US)
Pages (from-to)326-335
Number of pages10
JournalBritish journal of haematology
Volume162
Issue number3
DOIs
StatePublished - Aug 2013

Keywords

  • Histone deacetylase inhibitors
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Panobinostat

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis'. Together they form a unique fingerprint.

Cite this